| |
Twice-Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
|
| |
| |
Reported by Jules Levin
Presented at the American Transplant Congress, May 18Ð22, 2013, Seattle, Washington
The 13th Joint Annual Congress of the American Society of Transplant Surgeons and The American Society of Transplantation
Robert S. Brown, Jr., MD, MPH1; Mark W. Russo, MD2; Josh Levitsky, MD3; Kimberly A. Brown, MD4; Robert J. Fontana, MD5; Hugo Vargas, MD6; Eric Yoshida, MD7; Mohammad Bsharat, PhD8; Raymond Rubin, MD8
1Columbia University, New York, NY, USA; 2Carolinas Medical Center, Charlotte, NC, USA; 3Northwestern University, Chicago, IL, USA; 4Henry Ford Hospital, Detroit, MI, USA; 5University of Michigan, Ann Arbor, MI, USA; 6Mayo Clinic, Scottsdale, AZ, USA;
7University of British Columbia, Vancouver, British Columbia, CAN;
8Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
|
|
| |
| |
|
|
|
